Literature DB >> 23041830

CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer.

Sabina Davidsson1, Anna-Lena Ohlson, Swen-Olof Andersson, Katja Fall, Allison Meisner, Michelangelo Fiorentino, Ove Andrén, Jennifer R Rider.   

Abstract

Prostate cancer represents a major contributor to cancer mortality, but the majority of men with prostate cancer will die of other causes. Thus, a challenge is identifying potentially lethal disease at diagnosis. Conflicting results have been reported when investigating the relationship between infiltration of lymphocytes and survival in prostate cancer. One of the mechanisms suggested is the recruitment of regulatory T cells (T(regs)), a subpopulation of T cells that have a role in promoting tumor growth. T(regs) counteract tumor rejection through suppressive functions on the anti-immune response but their prognostic significance is still unknown. We report here the results of a conducted case-control study nested in a cohort of men treated with transurethral resection of the prostate and diagnosed incidentally with prostate cancer. Cases are men who died of prostate cancer (n=261) and controls are men who survived >10 years after their diagnosis (n=474). Infiltration of both T(helper) and T(cytotoxic) cells was frequently observed and the majority of the T(regs) were CD4(+). T(helper) or T(cytotoxic) cells were not associated with lethal prostate cancer. However, we found a nearly twofold increased risk of lethal prostate cancer when comparing the highest with the lowest quartile of CD4(+) T(regs) cells (95% confidence interval: 1.3-2.9). Our conclusion is that men with greater numbers of CD4(+) T(regs) in their prostate tumor environment have an increased risk of dying of prostate cancer. Identification of CD4(+) T(regs) in tumor tissue may predict clinically relevant disease at time of diagnosis independently of other clinical factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041830     DOI: 10.1038/modpathol.2012.164

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  31 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 3.  The inflammatory microenvironment and microbiome in prostate cancer development.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

Review 4.  The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.

Authors:  Haoqing Shi; Xiangjie Qi; Bin Ma; Yanwei Cao; Lina Wang; Lijiang Sun; Haitao Niu
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 5.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

6.  T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation.

Authors:  Michael A Cerqueira; Karen L Ferrari; Amilcar C de Mattos; Carlos R Monti; Leonardo Oliveira Reis
Journal:  World J Urol       Date:  2019-07-01       Impact factor: 4.226

7.  Bisphenol A Disrupts HNF4α-Regulated Gene Networks Linking to Prostate Preneoplasia and Immune Disruption in Noble Rats.

Authors:  Hung-Ming Lam; Shuk-Mei Ho; Jing Chen; Mario Medvedovic; Neville Ngai Chung Tam
Journal:  Endocrinology       Date:  2015-10-23       Impact factor: 4.736

Review 8.  Regulation of prostate cancer progression by the tumor microenvironment.

Authors:  Stephen L Shiao; Gina Chia-Yi Chu; Leland W K Chung
Journal:  Cancer Lett       Date:  2016-01-28       Impact factor: 8.679

Review 9.  Drug discovery in advanced prostate cancer: translating biology into therapy.

Authors:  Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

Review 10.  The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

Authors:  Nicole J Flynn; Rajasekharan Somasundaram; Kimberly M Arnold; Jennifer Sims-Mourtada
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.